SCHEMBL5535849

SCHEMBL5535849

[CH2]c1ccc(Oc2c(C)cccc2C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.41
LPAR1 Q92633 3/20 0.40
LPAR5 Q9H1C0 3/20 0.40
HSP90AA1 P07900 1/20 0.36
FFAR1 O14842 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SCN4A P35499 3/20 0.34
LMNA P02545 2/20 0.34
CYP1A2 P05177 2/20 0.34
SCN1A P35498 2/20 0.34
SCN5A Q14524 2/20 0.34
SCN9A Q15858 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
KCNK3 O14649 1/20 0.34
CACNA1F O60840 1/20 0.34
KCNK2 O95069 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2089896 0.81 AR (0.44) ARALDH1A1NPBWR1MAPT
SCHEMBL9487846 0.79 LTA4H (0.52) ARLPAR1LPAR5FFAR1L3MBTL1
SCHEMBL16659204 0.78 TEAD4 (0.56) ARHSP90AA1CYP3A4TSHRMAOA
SCHEMBL437049 0.75 HSP90AA1 (0.50) ARHSP90AA1SCN4ALMNACYP1A2
SCHEMBL5541922 0.75 MAPK1 (0.52) ARL3MBTL1LMNACYP1A2CYP3A4
SCHEMBL921691 0.75 ST14 (0.55) LPAR1LPAR5FFAR1SCN4ALMNA
SCHEMBL5539624 0.74 LPAR1 (0.40) ARLPAR1LPAR5HSP90AA1SLC6A4
SCHEMBL922381 0.74 AR (0.41) ARLPAR1LPAR5HSP90AA1FFAR1
SCHEMBL5544007 0.74 MAPT (0.41) LPAR1LPAR5CYP1A2CYP2A6MAPT
SCHEMBL17508315 0.74 ALDH1A1 (0.50) ARLPAR1LPAR5FFAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 AR 254/4885LPAR1 2085/4885LPAR5 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.